News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,091 Results
Type
Article (43911)
Company Profile (438)
Press Release (673742)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (209200)
Career Advice (2058)
Deals (36074)
Drug Delivery (104)
Drug Development (83920)
Employer Resources (174)
FDA (16568)
Job Trends (15170)
News (354016)
Policy (33330)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2662)
Accelerated approval (6)
Adcomms (24)
Allergies (85)
Alliances (51081)
ALS (94)
Alzheimer's disease (1427)
Antibody-drug conjugate (ADC) (139)
Approvals (16556)
Artificial intelligence (262)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11894)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (330)
Bladder cancer (81)
Brain cancer (26)
Breast cancer (281)
Cancer (2262)
Cardiovascular disease (184)
Career advice (1719)
Career pathing (30)
CAR-T (152)
Cell therapy (432)
Cervical cancer (19)
Clinical research (68017)
Collaboration (865)
Compensation (530)
Complete response letters (24)
COVID-19 (2651)
CRISPR (42)
C-suite (244)
Cystic fibrosis (106)
Data (2163)
Decentralized trials (2)
Denatured (28)
Depression (50)
Diabetes (269)
Diagnostics (6432)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (107)
Drug shortages (26)
Duchenne muscular dystrophy (101)
Earnings (87775)
Editorial (39)
Employer branding (21)
Employer resources (148)
Events (116033)
Executive appointments (728)
FDA (17812)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (779)
Gene editing (109)
Generative AI (20)
Gene therapy (319)
GLP-1 (747)
Government (4521)
Grass and pollen (4)
Guidances (53)
Healthcare (19279)
Huntington's disease (24)
IgA nephropathy (29)
Immunology and inflammation (127)
Indications (29)
Infectious disease (2797)
Inflammatory bowel disease (141)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (96)
Interviews (317)
IPO (16802)
IRA (43)
Job creations (3723)
Job search strategy (1459)
Kidney cancer (10)
Labor market (38)
Layoffs (497)
Leadership (17)
Legal (8070)
Liver cancer (74)
Lung cancer (320)
Lymphoma (152)
Machine learning (6)
Management (58)
Manufacturing (306)
MASH (68)
Medical device (13639)
Medtech (13644)
Mergers & acquisitions (19797)
Metabolic disorders (706)
Multiple sclerosis (80)
NASH (19)
Neurodegenerative disease (98)
Neuropsychiatric disorders (33)
Neuroscience (1986)
NextGen: Class of 2025 (6822)
Non-profit (4574)
Northern California (2645)
Now hiring (39)
Obesity (382)
Opinion (231)
Ovarian cancer (75)
Pain (95)
Pancreatic cancer (82)
Parkinson's disease (154)
Partnered (21)
Patents (232)
Patient recruitment (106)
Peanut (47)
People (58778)
Pharmaceutical (87)
Pharmacy benefit managers (19)
Phase I (21330)
Phase II (29970)
Phase III (22206)
Pipeline (1169)
Policy (144)
Postmarket research (2658)
Preclinical (9137)
Press Release (68)
Prostate cancer (107)
Psychedelics (37)
Radiopharmaceuticals (262)
Rare diseases (401)
Real estate (6036)
Recruiting (67)
Regulatory (22870)
Reports (46)
Research institute (2432)
Resumes & cover letters (359)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (74)
Series A (139)
Series B (89)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2284)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3782)
State (2)
Stomach cancer (14)
Supply chain (68)
Tariffs (34)
The Weekly (48)
United States (23185)
Vaccines (707)
Venture capitalists (43)
Weight loss (253)
Women's health (37)
Worklife (16)
Date
Today (129)
Last 7 days (707)
Last 30 days (2418)
Last 365 days (33884)
2025 (10284)
2024 (36369)
2023 (41079)
2022 (52357)
2021 (56867)
2020 (55071)
2019 (47705)
2018 (35931)
2017 (33193)
2016 (32641)
2015 (38646)
2014 (32376)
2013 (27350)
2012 (29456)
2011 (30117)
2010 (28254)
Location
Africa (753)
Alabama (57)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39499)
Australia (6602)
California (6100)
Canada (1988)
China (523)
Colorado (268)
Connecticut (281)
Delaware (144)
Europe (86619)
Florida (885)
Georgia (203)
Idaho (57)
Illinois (541)
India (25)
Indiana (309)
Iowa (12)
Japan (159)
Kansas (105)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (894)
Massachusetts (4636)
Michigan (218)
Minnesota (393)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (66)
New Jersey (1728)
New Mexico (30)
New York (1723)
North Carolina (1020)
North Dakota (7)
Northern California (2645)
Ohio (202)
Oklahoma (14)
Oregon (39)
Pennsylvania (1355)
Puerto Rico (11)
Rhode Island (33)
South America (1127)
South Carolina (22)
South Dakota (1)
Southern California (2284)
Tennessee (101)
Texas (901)
Utah (181)
Virginia (147)
Washington D.C. (63)
Washington State (568)
West Virginia (3)
Wisconsin (54)
718,091 Results for "pain therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pain
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.
February 24, 2025
·
9 min read
·
Tristan Manalac
Press Releases
Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain
April 9, 2025
·
3 min read
FDA
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.
January 30, 2025
·
4 min read
·
Heather McKenzie
Editorial
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by
BioSpace
’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid epidemic.
February 7, 2025
·
3 min read
·
Heather McKenzie
Press Releases
Navega Therapeutics Announces CIRM Grant for Treatment of Chronic Pain
February 5, 2025
·
3 min read
Pain
Algiax’s Non-Opioid Drug Reduces Neuropathic Pain in Mid-Stage Trial
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx as the first novel mechanism for acute pain in decades.
February 4, 2025
·
1 min read
·
Dan Samorodnitsky
Pain
AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still believes in the promise of its candidate as Vertex Pharmaceuticals’ first-in-class drug Journavx opens up the non-opioid space.
February 18, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in Patients with Symptomatic Disc Degeneration
April 9, 2025
·
2 min read
Press Releases
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
March 4, 2025
·
5 min read
Press Releases
Cancer Pain Market Size to Reach USD 2,614.25 Million by 2035, Impelled by Escalating Cancer Incidence and Advancements in Pain Control Therapies
February 14, 2025
·
8 min read
1 of 71,810
Next
